Influence of recipients' immune status on effectiveness of adoptive immunotherapy with TAA specific T lymphocytes and interleukin-2 in CBA polyoma mice.
We investigated causes of failure of adoptive immunotherapy in 30% of tumor implanted CBA mice which were administered Il-2 and DTH mediating T lymphocytes. The lymphocytes were taken from polyoma implanted animals and restimulated in vitro with soluble polyoma TAA and Il-2. A close correlation was observed between the percentage of tumor implanted mice for whom the therapy was ineffective and the percentage of healthy mice with low immune response assessed in vitro by blastogenic response to ConA, PHA, and allogeneic lymphocytes. Il-2 administration was indispensable to complete tumor inhibition. The level of DTH to polyoma TAA in tumor implanted recipients was correlated neither with effectiveness of the therapy nor with immune status of the recipients, assessed by above criteria, and it was diminished by the Il-2.
Ochalek
T
T
Department of Pathology, Maria Sklodowska-Curie Memorial Institute, Krakow, Poland.
D000818:Animals; D002455:Cell Division; D006968:Hypersensitivity, Delayed / Q000276:immunology; D007113:Immunity, Innate; D016219:Immunotherapy, Adoptive; D007376:Interleukin-2 / Q000627:therapeutic use*; D008213:Lymphocyte Activation / Q000187:drug effects; D051379:Mice; D008808:Mice, Inbred CBA; D008934:Mitogens / Q000494:pharmacology; D011120:Polyomavirus; D013154:Spleen / Q000166:cytology / Q000187:drug effects / Q000276:immunology; D013601:T-Lymphocytes / Q000276:immunology*; D014412:Tumor Virus Infections / Q000276:immunology / Q000628:therapy*
D007376:Interleukin-2; D008934:Mitogens